Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials
Symptomatic uterine fibroids are burdensome to live with: they are associated with symptom-related distress, affect daily activities and reduce health-related quality of life. The LIBERTY randomized clinical trials showed that oral relugolix combination therapy (once-daily relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) significantly improved fibroid-associated symptoms and conditions including heavy menstrual bleeding and pain, as well as anemia, and was well-tolerated. (Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - November 9, 2022 Category: OBGYN Authors: Elizabeth A. Stewart, Andrea S. Lukes, Roberta Venturella, Yulan Li, Elke Hunsche, Rachel B. Wagman, Ayman Al-hendy Tags: Original Research: Gynecology Source Type: research
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
AbstractAn oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate (Ryeqo®; Myfembree®) has been approved for the management of heavy menstrual bleeding associated with uterine fibroids in the USA and management of moderate to severe symptoms of uterine fibroids in the EU. Relugolix is a gonadotropin releasing hormone (GnRH) receptor antagonist that decreases serum estradiol and progesterone concentrations to postmenopausal levels. The addition of estradiol/norethisterone acetate to relugolix ameliorates relugolix-induced bone loss and hot flush. In the two phase 3 LIBERTY ...
Source: Drugs - November 4, 2022 Category: Drugs & Pharmacology Source Type: research
Menopausal hormone therapy with conjugated equine estrogen is associated with a higher risk of hemorrhagic stroke than therapy with estradiol: a retrospective population-based cohort study
Estrogen therapy is prescribed for women without a uterus. For women with intact uteri, progestogens should be added to protect against endometrial hyperplasia. Different estrogen profiles may cause different side effects and beneficial clinical outcomes [1]. Different forms of estrogen also have different serum E2 concentrations; a previous study demonstrated that 1 mg E2 was equivalent to 0.4 mg CEE [1]. Progestin includes medroxyprogesterone acetate (MPA) and norethindrone acetate (NE). In Taiwan, the most common MHT for patients with an intact uterus are CEE (0.625 mg) or E2 (2 mg) combined with 5 mg MPA or ...
Source: Maturitas - August 1, 2022 Category: Primary Care Authors: Wei-Chuan Chang, Jen-Hung Wang, Dah-Ching Ding Tags: Original article Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
